Aragon Pharmaceuticals Inc.
http://www.aragonpharmaceuticals.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aragon Pharmaceuticals Inc.
J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide
Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.
J&J’s Stoffels On Actelion’s ‘Exquisite’ Researchers, India TB R&D Plans
J&J’s chief scientific officer Dr. Paul Stoffels tells Scrip that flexibility is a hallmark of how the company goes about its collaborations, including the new $30bn deal with Actelion. Stoffels is also hoping to progress the science for a new TB medicine via a unique collaboration in India.
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments
VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.